These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28669848)

  • 41. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?
    Kim KH; Lee J; Lee JI; Nam DH; Kong DS; Ahn YC; Park HC; Kwon OJ; Kim H; Chang MH; Yi SY; Ji SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2010 May; 68(2):258-63. PubMed ID: 19592127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases.
    Hsiao SH; Chung CL; Chou YT; Lee HL; Lin SE; Liu HE
    Lung Cancer; 2013 Nov; 82(2):319-23. PubMed ID: 24018025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    Tan WL; Ng QS; Lim C; Tan EH; Toh CK; Ang MK; Kanesvaran R; Jain A; Tan DSW; Lim DW
    BMC Cancer; 2018 Dec; 18(1):1198. PubMed ID: 30509246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis.
    Li WY; Zhao TT; Xu HM; Wang ZN; Xu YY; Han Y; Song YX; Wu JH; Xu H; Yin SC; Liu XY; Miao ZF
    BMC Cancer; 2019 Feb; 19(1):145. PubMed ID: 30760227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.
    Caballero JA; Sneed PK; Lamborn KR; Ma L; Denduluri S; Nakamura JL; Barani IJ; McDermott MW
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):303-9. PubMed ID: 22079723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC.
    Wang BX; Ou W; Mao XY; Liu Z; Wu HQ; Wang SY
    Clin Neurol Neurosurg; 2017 Sep; 160():96-100. PubMed ID: 28704781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.
    Berghoff AS; Magerle M; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckman K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; Preusser M; Birner P
    APMIS; 2013 Dec; 121(12):1144-52. PubMed ID: 23756255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
    Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.
    Tomasini P; Serdjebi C; Khobta N; Metellus P; Ouafik L; Nanni I; Greillier L; Loundou A; Fina F; Mascaux C; Barlesi F
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EGFR mutation status on brain metastases from non-small cell lung cancer.
    Hsu F; De Caluwe A; Anderson D; Nichol A; Toriumi T; Ho C
    Lung Cancer; 2016 Jun; 96():101-7. PubMed ID: 27133758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer.
    Kaul D; Angelidis A; Budach V; Ghadjar P; Kufeld M; Badakhshi H
    Radiat Oncol; 2015 Nov; 10():244. PubMed ID: 26611493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated 
Non-small Cell Lung Cancer and Brain Metastases].
    Liu G; Zhang X; Tian C; Xia G; Liu P; Zhang Q; Li X; Zhang H; Qin N; Wang J; Zhang S
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):501-7. PubMed ID: 27561798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
    Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
    J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.
    Lee Y; Lee GK; Hwang JA; Yun T; Kim HT; Lee JS
    Clin Lung Cancer; 2015 Jan; 16(1):46-50. PubMed ID: 25450875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers.
    Remon J; Alvarez-Berdugo D; Majem M; Moran T; Reguart N; Lianes P
    Clin Transl Oncol; 2016 Feb; 18(2):153-9. PubMed ID: 26199015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
    Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The outcome of bifocal surgical resection in non-small cell lung cancer with synchronous brain metastases: results of a single center retrospective study.
    Yuksel C; Bozkurt M; Yenigun BM; Enon S; Ozkan M; Kose SK; Cangir AK
    Thorac Cardiovasc Surg; 2014 Oct; 62(7):605-11. PubMed ID: 24310312
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
    Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.
    Takenaka T; Takenoyama M; Yamaguchi M; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Yoshida T; Shiraishi Y; Morodomi Y; Hirai F; Taguchi K; Shimokawa M; Seto T; Ichinose Y
    Eur J Cardiothorac Surg; 2015 Mar; 47(3):550-5. PubMed ID: 24894095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.